GW Henssler & Associates Ltd. lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 21,415 shares of the medical research company’s stock after selling 229 shares during the quarter. GW Henssler & Associates Ltd.’s holdings in Thermo Fisher Scientific were worth $9,773,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the business. Meeder Asset Management Inc. grew its position in Thermo Fisher Scientific by 241.8% in the first quarter. Meeder Asset Management Inc. now owns 14,791 shares of the medical research company’s stock worth $6,750,000 after acquiring an additional 10,463 shares in the last quarter. JustInvest LLC grew its position in Thermo Fisher Scientific by 7.4% in the first quarter. JustInvest LLC now owns 5,458 shares of the medical research company’s stock worth $2,491,000 after acquiring an additional 377 shares in the last quarter. DAGCO Inc. grew its position in Thermo Fisher Scientific by 2.1% in the first quarter. DAGCO Inc. now owns 4,572 shares of the medical research company’s stock worth $2,087,000 after acquiring an additional 92 shares in the last quarter. Park Avenue Securities LLC grew its position in Thermo Fisher Scientific by 11.5% in the first quarter. Park Avenue Securities LLC now owns 13,672 shares of the medical research company’s stock worth $6,240,000 after acquiring an additional 1,410 shares in the last quarter. Finally, Lindbrook Capital LLC grew its position in Thermo Fisher Scientific by 5.6% in the first quarter. Lindbrook Capital LLC now owns 568 shares of the medical research company’s stock worth $259,000 after acquiring an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 87.17% of the company’s stock.

Several analysts recently issued reports on TMO shares. Robert W. Baird reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a report on Monday. KeyCorp raised shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $520.00 price objective for the company in a report on Wednesday, March 24th. BTIG Research upped their price objective on shares of Thermo Fisher Scientific from $540.00 to $590.00 and gave the stock a “buy” rating in a report on Wednesday, February 3rd. Credit Suisse Group upped their price objective on shares of Thermo Fisher Scientific from $556.00 to $580.00 in a report on Tuesday, January 12th. Finally, Cowen upped their target price on shares of Thermo Fisher Scientific from $525.00 to $585.00 and gave the company an “outperform” rating in a research note on Tuesday, February 2nd. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Thermo Fisher Scientific has an average rating of “Buy” and an average target price of $534.45.

NYSE:TMO traded down $5.89 during mid-day trading on Tuesday, reaching $461.49. 20,154 shares of the company were exchanged, compared to its average volume of 1,796,376. Thermo Fisher Scientific Inc. has a 12 month low of $324.35 and a 12 month high of $532.57. The company has a fifty day moving average of $468.08 and a 200 day moving average of $476.02. The company has a quick ratio of 2.31, a current ratio of 2.93 and a debt-to-equity ratio of 0.66. The stock has a market cap of $181.37 billion, a PE ratio of 38.31, a PEG ratio of 1.40 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, April 29th. The medical research company reported $7.21 EPS for the quarter, topping analysts’ consensus estimates of $6.69 by $0.52. The firm had revenue of $9.91 billion for the quarter, compared to analyst estimates of $9.69 billion. Thermo Fisher Scientific had a net margin of 17.12% and a return on equity of 21.35%. The company’s revenue was up 59.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.94 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 19.03 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, April 16th. Stockholders of record on Tuesday, March 16th were paid a $0.26 dividend. This represents a $1.04 annualized dividend and a dividend yield of 0.23%. The ex-dividend date was Monday, March 15th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.22. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 8.42%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Recommended Story: How mutual funds make money

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.